1623764-17-9

Upstream product

• 1301146-84-8 4-bromo-2-chloro-1-(methoxymethoxy)benzene 
• 1623766-65-3 2-(3-chloro-4-(methoxymethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1623766-30-2 (R)-N-(2,4-dimethoxybenzyl)-N-(2-hydroxypropyl)-3,3-dimethoxypropanamide 
• 1623766-31-3 (R)-4-(2,4-dimethoxybenzyl)-2-methyl-3,4-dihydro-1,4-oxazepin-5(2H)-one 
• 1623766-32-4 (R)-4-(2,4-dimethoxybenzyl)-2-methyl-1,4-oxazepan-5-one 
• 1623766-34-6 (R)-2-methyl-1,4-oxazepan-5-one 
• 1623766-33-5 (R)-5-methoxy-2-methyl-2,3,6,7-tetrahydro-1,4-oxazepine 
• 1623767-38-3 (R)-1-bromo-3-(3-chloro-4-(methoxymethoxy)phenyl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine 
• 1623767-39-4 (R)-3-(3-chloro-4-(methoxymethoxy)phenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine 
• 1623767-40-7 (R)-2-chloro-4-[1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepin-3-yl]phenol 
• 75-26-3 isopropyl bromide 

Relevant academic research and scientific papers

Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative

A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving th